BioSpace News Archive

- Highly innovative genome editing technology platform accelerates and broadens ElevateBio’s cell and gene therapy enabling technologies - LifeEDIT Therapeutics to develop its own pipeline of potentially life-transforming therapeutics - LifeEDIT Therapeutics to leverage its novel gene editing platform with strategic partners including ElevateBio portfolio companies

— Milestone Achievement Reflects First Investigational Candidate to Emerge Under Multi-Target Collaboration and Triggers $10 Million Payment to Dicerna — – Lilly Targeting Initiation of Phase 1 Clinical Trial of LY3561774 by Year-End 2020 –

Day-90 Analysis of FX-322 Phase 2a Study for Acquired Sensorineural Hearing Loss (SNHL) Planned for Late Q1 2021; End of Study Readout Planned in Late Q2 2021

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in the Craig-Hallum Capital Group’s annual Alpha Select Conference on Tuesday November 17, 2020. The conference consists of one-on-one and small group meetings, which will t

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX:VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it has been invited to present at Stifel Virtual Healthcare Conference, being held on Wednesday, November 18, 2020.

Advancing American kidney health has been identified as a key public health priority by a 2019 Presidential Executive Order

Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced the expansion of Myriad myChoice® tumor testing in several European markets and China.

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~ ~ No Clinical Safety or Efficacy Issues Identified ; No Additional Studies Required for PEDMARK™ ~ ~ The Company Has Approximately $33 Million in Cash and No Outstanding Debt ~

Regeneron Pharmaceuticals, Inc. announced that it has been included on the highly selective Dow Jones Sustainability World Index for the second consecutive year.

Dr. Safadi, the study’s Principal Investigator: “Namodenoson’s very impressive study data may result in a promising drug for the treatment of NAFLD/NASH due to the combination of good efficacy and favorable safety.”